Moleculin Biotech, Inc. (MBRX) Operating cash flow 2016–2025
Moleculin Biotech, Inc. (MBRX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$22.7MFY2025 · since FY2016: -$3.8M → -$22.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$22.7M | +4.7% |
| FY2024 | -$23.9M | -1.1% |
| FY2023 | -$23.6M | +14.6% |
| FY2022 | -$27.6M | -45.8% |
| FY2021 | -$19.0M | -6.6% |
| FY2020 | -$17.8M | -3.3% |
| FY2019 | -$17.2M | -40.9% |
| FY2018 | -$12.2M | -66.6% |
| FY2017 | -$7.3M | -94.5% |
| FY2016 | -$3.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More MBRX financial trends
MBRX RevenueMBRX Net incomeMBRX Net marginMBRX Gross profitMBRX Gross marginMBRX Operating incomeMBRX Operating marginMBRX Free cash flowMBRX Capital expendituresMBRX Return on equityMBRX Stock buybacksMBRX Dividends paidMBRX Total assetsMBRX Total liabilitiesMBRX Shareholders’ equityMBRX overview →